Transthyretin Amyloidosis (ATTR) With Cardiomyopathy research hub
3 indexed studies · 2 currently recruiting
- recruitingPHASE3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
This study looks at a new treatment called NTLA-2001 for a heart condition called transthyretin amyloidosis with cardiomyopathy (ATTR-CM). It compares a single dose of NTLA-2001 with a dummy drug (placebo) to see if it's safe and effective for people with this condition.
United States · Argentina · Australia - enrolling by invitationPHASE3
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study looks at a medicine called vutrisiran for a heart condition called transthyretin amyloidosis (ATTR cardiomyopathy). It aims to understand how safe and effective vutrisiran is for patients who have already been taking it or switched from a similar medicine called patisiran.
United States · Argentina · Austria - active not recruitingPHASE3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is looking at a new medicine called vutrisiran for people with a heart condition called transthyretin amyloidosis (ATTR) cardiomyopathy. It aims to see if the medicine can help improve the condition and if it's safe compared to a dummy treatment.
United States · Argentina · Australia